G
Giulia Alunni
Researcher at University of Perugia
Publications - 2
Citations - 88
Giulia Alunni is an academic researcher from University of Perugia. The author has contributed to research in topics: Hazard ratio & Minimal residual disease. The author has an hindex of 2, co-authored 2 publications receiving 62 citations.
Papers
More filters
Journal ArticleDOI
Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
Monica Bocchia,Anna Sicuranza,Elisabetta Abruzzese,Alessandra Iurlo,Santina Sirianni,Antonella Gozzini,Sara Galimberti,Lara Aprile,Bruno Martino,Patrizia Pregno,Federica Sorà,Giulia Alunni,Carmen Fava,Fausto Castagnetti,Luca Puccetti,Massimo Breccia,Daniele Cattaneo,Marzia Defina,Olga Mulas,Claudia Baratè,Giovanni Caocci,Simona Sica,Alessandro Gozzetti,Luigiana Luciano,Monica Crugnola,Mario Annunziata,Mario Tiribelli,Paola Pacelli,Ilaria Ferrigno,Emilio Usala,Nicola Sgherza,Gianantonio Rosti,Alberto Bosi,Donatella Raspadori +33 more
TL;DR: This cross-sectional study provides the first evidence that “circulating” CML LSCs persist in the majority of CML patients in molecular response while on TKI treatment and even after TKI discontinuation.
Journal ArticleDOI
Real‐world experience with decitabine as a first‐line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy
Monica Bocchia,Anna Candoni,Erika Borlenghi,Marzia Defina,Carla Filì,Chiara Cattaneo,Vincenzo Sammartano,Renato Fanin,Margherita Sciumé,Anna Sicuranza,Silvia Imbergamo,Marta Riva,Nicola Stefano Fracchiolla,Roberto Latagliata,Emanuela Caizzi,Francesco Mazziotta,Giulia Alunni,Eros Di Bona,Monica Crugnola,Marianna Rossi,Ugo Consoli,Giulia Fontanelli,Giuseppina Greco,Gianpaolo Nadali,Francesco Rotondo,Elisabetta Todisco,Catia Bigazzi,Enrico Capochiani,Alfredo Molteni,Massimo Bernardi,Monica Fumagalli,Michela Rondoni,Barbara Scappini,Anna Ermacora,Federico Simonetti,Michele Gottardi,Daniela Lambertenghi Deliliers,Mariagrazia Michieli,Claudia Basilico,Carlotta Galeone,Claudio Pelucchi,Giuseppe Rossi +41 more
TL;DR: This pooled analysis of clinical care studies confirmed the effectiveness of decitabine as first‐line therapy for AML in elderly patients unfit for intensive chemotherapy, and an adverse cytogenetic profile and a higher WBC count at diagnosis were, in this real life setting, unfavourable predictors of survival.